Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's ...

December is a month for nostalgia, and Paramount+ is bringing back a host of classic films that are sure to appeal to a wide audience. Notable titles arriving on December 1 include: These films not ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s one of the largest ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

A weapon used by Mel Gibson while he played the Scots hero of William Wallace in Braveheart has sold for over £8,000 at auction. Fans of the award winning film were given the opportunity to snap up ...

Mel Gibson has hinted that he could film at Scotland’s newest movie studio... if the price is right. The Hollywood icon reacted positively to the news that his iconic Braveheart film has inspired the ...

Jiangsu Hengrui Pharmaceuticals has entered into an exclusive licensing agreement with U.S.-based Braveheart Bio for its novel small-molecule cardiac myosin inhibitor, HRS-1893, currently in Phase III ...

Jiangsu Hengrui Pharmaceuticals, a Chinese developer of novel drugs, could receive up to US$1.01 billion in milestone payments after granting a US company exclusive rights to develop a heart disease ...